Nektar Therapeutics (NKTR) Tops Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Nektar Therapeutics (NKTR) PT Raised to $35 at Jefferies; Plans '181 NDA 2 Years Early
November 8, 2017 8:28 AM ESTJefferies raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $35.00 (from $23.00) while maintaining a Buy rating following Q3 results.
Analyst David Steinberg said the big news was NKTR disclosed that they are now planning to file an NDA for 181 in Apr... More
